The Lobbying Register, read carefully Epicycle

Returns

Every filed return on the register. Filter, then open any return on lobbying.ie to read it in full.

Clear all

Showing returns filed by Novartis Ireland Limited .

Filed returns
9
match these filters
Matching filed returns per period 0 1 2 3 5 Jan–Apr 2025: 1 filed returns May–Aug 2025: 5 filed returns Sep–Dec 2025: 2 filed returns Jan–Apr 2026: 1 filed returns 2025 2026
Filed returns per four-month period Click a column to list its returns.
PeriodRegistrantPolicy areaSubject, as filedOfficials namedLink
Jan–Apr 2026 Novartis Ireland Limited Foreign Affairs Policy Agenda for the EU Presidency (Public policy or programme) 1 On lobbying.ie
Sep–Dec 2025 Novartis Ireland Limited Health Forwarding letter to Dept of Health about access to innovative treatment for Irish patients (Public policy or programme) 6 On lobbying.ie
Sep–Dec 2025 Novartis Ireland Limited Health Advocate for Life Science Strategy (Public policy or programme) 7 On lobbying.ie
May–Aug 2025 Novartis Ireland Limited Health Letter to Tanaiste about access to innovative treatment for Irish patients (Public policy or programme) 5 On lobbying.ie
May–Aug 2025 Novartis Ireland Limited EU Affairs Attending a meeting organised by Hanover with the Minister for EU Affairs (Public policy or programme) 1 On lobbying.ie
May–Aug 2025 Novartis Ireland Limited Foreign Affairs EU Presidency (Public policy or programme) 1 On lobbying.ie
May–Aug 2025 Novartis Ireland Limited Health Rare diseases conference, as an official event of the Irish EU Presidency (Public policy or programme) 6 On lobbying.ie
May–Aug 2025 Novartis Ireland Limited Health IPHA Industry meeting - engagement on trade and tariff issues (Legislation) 1 On lobbying.ie
Jan–Apr 2025 Novartis Ireland Limited Health Competitivness, government needs to be perceived as pro-innovation (Legislation) 1 On lobbying.ie

Policy areas in these returns

Public policy areaFiled returnsShareRelative to the largest
Health 6 66.7%
Foreign Affairs 2 22.2%
EU Affairs 1 11.1%